Home > Insider Trading > Novartis A G

Novartis A G (NVS)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
111 - 120
Next >>

Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT)

Novartis AG (ADR) (NYSE:NVS) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will jointly develop Conatus drug emricasan. This has resulted from the duo’s agreement under which the small U.S.

Keep Reading →

December 20th, 2016 - News Stock Analysis

What Smart Money Has To Say About Novartis AG (ADR) (NVS)

Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don...

Keep Reading →

December 5th, 2016 - Hedge Funds News

Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.

Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp.

Keep Reading →

November 22nd, 2016 - News Stock Analysis

5 Healthcare Stocks Kahn Brothers Is Bullish On

Kahn Brothers is a New York-based hedge fund which was founded by famous American businessman Irving Kahn (who recently passed away at the age of 109 as the Oldest Money Manager) in 1978.

Keep Reading →

November 8th, 2016 - Hedge Fund Analysis Hedge Funds News

Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer

Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance.

Keep Reading →

November 2nd, 2016 - News

Novartis AG (NVS) Relocates NITD To California

James Bradner, Novartis AG (NYSE:NVS) Novartis Institutes for BioMedical Research President, has recently confirmed that the company will move the Novartis Institute for Tropical Diseases (NITD) to California...

Keep Reading →

October 6th, 2016 - News Stock Analysis

Does Novartis AG (NVS) Have The Solution For Malaria?

Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine.

Keep Reading →

September 22nd, 2016 - News Stock Analysis

Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data

Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients ...

Keep Reading →

August 29th, 2016 - News Stock Analysis

Novartis AG (NVS) Announces Positive Phase III Results For MS Drug

Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary progressive multiple sclerosis (SPMS), has met...

Keep Reading →

August 26th, 2016 - News Stock Analysis

Colombia Makes Good On Its Threat Against Novartis AG (NVS)

After negotiations with Novartis AG (NYSE:NVS) to lower the price of key leukemia drug Gleevec broke off, the Colombian government is set to take matters into its own hands.

Keep Reading →

June 10th, 2016 - News Stock Analysis